Back
Acta Physiologica 2006; Volume 186, Supplement 650
Joint Meeting of The German Society of Physiology and The Federation of European Physiological Societies 2006
3/26/2006-3/29/2006
Ludwig-Maximilians-University, Munich
ENDOTHELIAL PROTECTION, AT1 BLOCKADE AND CHOLESTEROL-DEPENDENT OXIDATIVE STRESS: THE EPAS TRIAL
Abstract number: OW02-7
Morawietz1 H, Erbs1 S, Holtz1 J, Schubert1 A, Krekler1 M, Goettsch1 W, Adams1 V, Mohr1 FW, Schuler1 G, Hambrecht1 R
1Dept. of Vascular Endothelium and Microcirculation, University of Technology Dresden
In the Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress (EPAS) trial, we tested in a clinical trial in PROBE (Prospective Randomized Open Label and Blinded Evaluation) design whether statin and angiotensin type 1 (AT1) receptor blocker therapies independently or in combination influence endothelial expression of anti- and proatherosclerotic genes and endothelial function in arteries of patients with coronary artery disease. Sixty patients with stable coronary artery disease undergoing elective coronary artery bypass grafting (CABG) surgery were randomized 4 weeks before surgery to: A) without inhibition of renin-angiotensin system or statin, B) statin without inhibition of renin-angiotensin system, C) AT1 blockade without statin, or D) combination of statin and AT1 blocker in same dosages. Groups did not differ in clinical characteristics. Statin and AT1 blocker therapy independently and in combination improved an endothelial expression quotient including mRNA expression of eNOS and CNP, divided by expression of oxLDL receptor LOX-1 and NAD(P)H oxidase subunit gp91phox and endothelial function in left internal mammary arteries obtained by CABG surgery. Our data support beneficial effects of both therapies in the treatment of coronary artery disease.
To cite this abstract, please use the following information:
Acta Physiologica 2006; Volume 186, Supplement 650 :OW02-7